Assembly BiosciencesASMB +10.25%32 EBIT per Share is $-1.73 as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,184 Biotechnology companies, Assembly Biosciences ranks better than 92.31% on this metric.
Assembly Biosciences's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.67.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.73.
During the past 3 years, the average EBIT per Share Growth Rate was 64.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 42.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Assembly Biosciences's EBIT per Share or its related term are showing as below:
ASMB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -29.2 Med: 20.8 Max: 64.1
Current: 64.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Assembly Biosciences was 64.10% per year. The lowest was -29.20% per year. And the median was 20.80% per year.
ASMB's 3-Year EBIT Growth Rate is ranked better than 92.31% of 1184
companies
in the Biotechnology industry
Industry Median: 15.45
vs ASMB: 64.10
Assembly Biosciences (NAS:ASMB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Assembly Biosciences EBIT per Share Related Terms
Assembly Biosciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a EBIT per Share of $-1.73 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #91 out of 1184 companies in the Biotechnology industry, placing it in the top 7.7%.
Is Assembly Biosciences' EBIT per Share too high?
Assembly Biosciences' current EBIT per Share is $-1.73. Based on the distribution chart, Assembly Biosciences ranks #91 out of 1184 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' EBIT per Share compare to MDXG and AGMB?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #91 out of 1184 companies for EBIT per Share. This places Assembly Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Assembly Biosciences and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current EBIT per Share is $-1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current EBIT per Share of $-1.73. The current EBIT per Share is $-1.73. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current EBIT per Share is $-1.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
